Evogene Amends its Collaboration Agreement With Bayer to Include Genome Editing Targets
Evogene Ltd. - Ordinary Shares (EVGN)
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
evogene.com/investor-relations
Company Research
Source: PR Newswire
REHOVOT, Israel, July 16, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announces today that after achieving positive results, its corn disease resistance research collaboration with the Crop Science Division of Bayer1 is being refocused on the identification of genome editing targets for evaluation against a broad range of corn diseases. Evogene will use its CPB (Computational Predictive Biology) platform to identify the required edits to improve disease resistance in corn. The edits will be based on Evogene-discovered genes and the accumulated knowledge achieved through this collaboration, focusing on altering gene expression or function. Any promising targets would be pursued by Bayer's in-house team for validation. The collaboration aims to develop improved corn seeds with resistance to fungal diseases. The overall annual value loss from corn diseases in the U.S. alone is estimated
Show less
Read more
Impact Snapshot
Event Time:
EVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVGN alerts
High impacting Evogene Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
EVGN
News
- Evogene Reports Third Quarter 2024 Financial ResultsPR Newswire
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results [Yahoo! Finance]Yahoo! Finance
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial ResultsPR Newswire
- Evogene Ltd. (NASDAQ: EVGN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field TrialsPR Newswire
EVGN
Earnings
- 3/7/24 - Beat
EVGN
Sec Filings
- 11/21/24 - Form 424B3
- 11/21/24 - Form 6-K
- 10/15/24 - Form SC
- EVGN's page on the SEC website